ATTENUATED REOVIRUS-BASED VACCINE COMPOSITION AND USE THEREOF

The present invention relates to an attenuated reovirus-based vaccine composition and a use thereof, the attenuated reovirus, according to the present invention, having the 251st to 455th amino acids of a sigma-1 protein of a capsid truncated such that when an epitope of an antigenic protein inducin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KIM, So Young, SONG, Ki Hoon, ALAIN, Tommy Michel, YOO, Haeng Jun, XIANG, Xiao, LEE, Yeon Sook, HAN, Sang Kyoung
Format:	Patent
Sprache:	eng ; fre ; kor
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to an attenuated reovirus-based vaccine composition and a use thereof, the attenuated reovirus, according to the present invention, having the 251st to 455th amino acids of a sigma-1 protein of a capsid truncated such that when an epitope of an antigenic protein inducing cancer or infectious disease is introduced to the truncated site of the sigma-1 protein, the epitope of the antigenic protein is stably expressed in a cell, and thus the effect is gained of exhibiting an immune response such as producing a neutralizing antibody or inducing cell-mediated immunity. As such, the present invention is expected to be usefully employable as a vaccine composition for cancer or infectious disease by introducing the epitope of the antigenic protein to the truncated site of the sigma-1 protein of the attenuated reovirus according to the present invention. La présente invention concerne une composition de vaccin à base de réovirus atténué et son utilisation, le réovirus atténué, selon la présente invention, ayant les 251ème à 455ème acides aminés d'une protéine sigma-1 d'une capside tronquée de telle sorte que, lorsqu'un épitope d'une protéine antigénique induisant un cancer ou une maladie infectieuse est introduit dans le site tronqué de la protéine sigma-1, l'épitope de la protéine antigénique est exprimé de manière stable dans une cellule, et on obtient ainsi l'effet de présentation d'une réponse immunitaire telle que la production d'un anticorps neutralisant ou l'induction d'une immunité à médiation cellulaire. En tant que telle, la présente invention est destinée à être utilisée utilement en tant que composition de vaccin contre le cancer ou une maladie infectieuse par introduction de l'épitope de la protéine antigénique dans le site tronqué de la protéine sigma-1 du réovirus atténué selon la présente invention. 본 발명은 약독화된 레오바이러스 기반의 백신 조성물 및 이의 용도에 관한 것으로서, 본 발명에 따른 약독화된 레오바이러스는 캡시드의 시그마 1 단백질에서 251-455번째 아미노산이 절단된 것으로서, 상기 절단된 시그마 1 단백질 부위에 암 또는 감염성 질환을 유발하는 항원 단백질의 에피토프를 도입할 경우, 항원 단백질의 에피토프가 세포 내에 안정적으로 발현하여, 중화 항체를 생성하거나 세포성 면역을 유도하는 등 면역 반응을 나타내는 효과를 가진다. 이에, 본 발명에 따른 약독화된 레오바이러스의 절단된 시그마 1 단백질 부위에 항원 단백질의 에피토프를 도입함으로써 암 또는 감염성 질환에 대한 백신 조성물로 유용하게 이용할 수 있을 것으로 기대된다.